Larvol Delta - Baseline-Characteristics-of-Patients-in-a-Phase-3-Randomized-PlaceboControlled-Trial-of-Admilparant-BMS986278-an-Oral-Lysophosphatidic-Acid-Receptor-1-Antagonist-in-Progressive-Pulmonary-Fibrosis

admilparant (BMS-986278) - BMS

https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3568671

Fernando Martinez, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next